LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in a fireside chat at the Piper Sandler

LONDON and NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 of its ordinary shares at a public offering price of $12.85 per

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of 5,000,000 of its ordinary shares.

Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months LONDON and NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced 12-month data

LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Gene Editing & Gene Therapy

MeiraGTx preparing to initiate Phase 3 trial of AAV-RPGR Plasmid production facility expected to be completed year-end 2020 LONDON and NEW YORK,, Nov. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced

12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented LONDON and NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that twelve-month results from the ongoing Phase 1/2

Data presented a t EURETINA   2020 Virtual Congress   show sustained improvements in retinal sensitivity at nine months S ignificant improvement s were also demonstrated in   the time taken to walk through   a   vision-guided mobility maze   at nine months LONDON and NEW YORK, Oct.

LONDON and NEW YORK , Sept. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Chardan 4 th Annual Genetic

- Nine-Month Follow-Up Data to be Presented - LONDON and NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month results from the ongoing Phase 1/2 clinical trial ( NCT03252847 ) of